Journal of Clinical Oncology · 2018 · 26 citations · 0 references
MedicinePharmacologyPharmacotherapyCancer PharmacologyClinical PharmacologyOncology PharmacotherapyCancer ImmunotherapyMultiple MyelomaClinical Trial ReportsLenalidomide TherapyMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma TreatmentRefractory Multiple MyelomaRelapsed Multiple Myeloma
8021 Background: KEYNOTE-183 (NCT02576977) evaluated pom + low-dose dex (SOC) ± pembro in patients (pts) with RRMM. Methods: Pts were randomized 1:1 to pembro (200 mg Q3W) + SOC (4 mg pom [d 1-21] + 40 mg dex [d 1, 8, 15, 22]) every 28 d vs SOC until progression (PD), unacceptable toxicity, withdrawal. Coprimary endpoints: PFS (2011 IMWG criteria), OS; secondary endpoints: safety, ORR. On July 3, 2017 based on interim data presented to the DMC, the FDA halted KEYNOTE-183. Results: 249/300 pts enrolled (125, pembro + SOC; 124, SOC) with median (range) age: 65 y (45-94) vs 67 y (22-90); 28 (22%) vs 17 (14%) pts had high-risk cytogenetics. Median (range) drug exposure was 123.5 d (2-477) vs 127 d (2-463); median 4.4 cycles. AEs with ≥5% difference between arms: neutropenia (38% vs 27%), nausea (17% vs 12%), pneumonia (23% vs 15%), ALT increase (10% vs 3%), headache (13% vs 4%). No SAEs had ≥5% difference between arms. In pembro + SOC arm, 21 (18%) pts had immune-mediated AEs: skin reaction (5%), pneumonitis (4%), hyperthyroidism (3%), infusion reaction (2%), myopathy (2%), myocarditis, iridocyclitis, hepatitis, Steven-Johnson syndrome (SJS; 1% each). 29 (23%) pts vs 21 (17%) died (16 from PD, 13 from AEs vs 18 from PD, 3 from AEs). 4 (3%) treatment related deaths occurred; 2 (1.5% [1 myocarditis, 1 SJS]) related to pembro. Median follow-up was 7.8 mo vs 8.6 mo. Median PFS: 5.6 mo vs 8.4 mo; HR, 1.53 (95% CI, 1.05-2.22); P= 0.98. Median TTP: 8.1 vs 8.7 mo. Median OS: not reached vs 15.2 mo; HR, 1.61 (95% CI, 0.91-2.85); P= 0.95. In a retrospective random forest analysis age, ECOG PS, disease stage, presence of plasmacytoma, double refractory status were more relevant contributors to death than treatment. A subsequent multivariable COX regression analysis showed age, ECOG, presence of plasmacytoma significantly contributed to risk of death. Age and presence of plasmacytoma were prognostic, while ECOG was prognostic and predictive of outcome with OS HR = 0.85 (ECOG 0) and OS HR = 2.3 (ECOG 1). Conclusions: The benefit-risk profile for combination of pembro, pom and dex is unfavorable for RRMM. Evaluation of T-cell subsets and cytokines along with long-term safety and survival follow-up is ongoing. Clinical trial information: NCT02576977.